TMC names former JLABS leader as the director of the Innovation Institute

taking control

Tom Luby will run the Texas Medical Center's Innovation Institute. Courtesy of TMC

The Texas Medical Center didn't have to go very far to find its new Innovation Institute director. Tom Luby, who most recently served as the site head for Johnson & Johnson Innovation's JLABS @ TMC, has been hired for the position.

"I am very excited to begin the next chapter in my journey at TMC Innovation," Luby says in a release. "My time at JLABS @ TMC has shown me the tremendous opportunity there is to work with a host of talented people and companies here in Houston. Now, I'm ready to expand my role and help take TMC Innovation as a collective unit to the next level."

Luby replaces Erik Halvorsen, who left abruptly in December. According to LinkedIn, Halvorsen is now the chief business and strategy officer for Houston-based FAR Biotech, for which he previously served on the board of directors. Lance Black, associate director at TMCx, served as the director in the interim for the past few months.

Prior to JLABS, Luby was in Boston at Johnson & Johnson and served as the new ventures lead. He has 14 years of research and design experience in the Boston area.

TMC as an organization has a lot up its sleeves, says President and CEO Bill McKeon in a release, and he trusts Luby to take the lead on innovation.

"With major developments in 2018, including the announcement of the forthcoming TMC3 translational research campus, Texas Medical Center is now on the fast track to becoming the third coast for life sciences, and TMC Innovation is a critical component in the ultimate realization of this goal," says McKeon. "Tom Luby is an outstanding individual, and his proven track record working with startups in Boston and within the walls of JLABS @ TMC will serve him well as he leads us through the next evolutionary phase of the TMC Innovation Institute."

Luby will oversee the med center's accelerator program, TMCx, which is currently in the midst of its eighth cohort.

Houston has just been named an emerging life sciences hub by CBRE. The recognition took job growth and lab space into consideration for the ranking.

Among this week's top stories is a feature on a Houston-based startup aiming to be the Uber or Lyft of personal trainers. Courtesy of Kanthaka

5 most popular innovation stories in Houston this week

Now trending

Editor's note: Houston saw big shake ups at some major innovation institutions this week, which made for some trending stories. And, per usual, readers enjoyed learning about local entrepreneurs fighting the good fight with their organizations.

Station Houston announces its transition into becoming a nonprofit

Station Houston's stakeholders voted in favor of the organization transitioning to a nonprofit. Station Houston/Facebook

Houston's startup scene just got a little more accessible. Station Houston's stakeholders voted to transition the organization to nonprofit status from the C-corp status it currently holds. The status change is effective January 1, 2019, for the acceleration hub, which is based in downtown Houston. The news was announced to its members in an email sent on December 13. Read the full story here.

Houston entrepreneur creates a network to link up with other blockchain professionals

The Houston Blockchain Alliance aims to connect and educate tech professionals in town. Getty Images

Houstonians traveling around the country might covet other cities for their mountain scapes, beaches, or more mild summers, but Mahesh Sashital envied the fact that other major cities had developed networks and organizations focused on connecting and educating tech professionals. Houston, it seems, was late to the party.

So, he decided to make his own blockchain-focused organization, and a few months ago, he launched the Houston Blockchain Alliance. Read the full story here.

3 Houston energy innovators to know this week

These energy startup leaders are the reason Houston will keep its "energy capital of the world" title. Courtesy images

Houston's known as the energy capital of the world, but it won't stay that way if the city as a whole doesn't work toward innovation. These three professionals started their own companies to improve efficiency and promote ingenuity in their fields. From drones and AI to quicker pipeline data access, this week's three innovators to know are the future of the energy industry. Read the full story here.

TMC Innovation Institute leader leaves the organization

Erik Halvorsen has reportedly left his position at the TMC Innovation Institute. Courtesy of TMC

Erik Halvorsen, director of the Texas Medical Center's Innovation Institute, has left his position, according to multiple reports.

TMC's medical device innovation team lead, Lance Black, was named as the interim replacement for Halvorsen, according to Xconomy. Black has been with TMC for almost two years. Read the full story here.

Get on-demand personal training from Houston-based app

Houston-based Kanthaka is the Uber or Lyft of personal training, and has recently expanded into the Austin market. Courtesy of Kanthaka

As a busy lawyer who traveled heavily for work, Sylvia Kampshoff found her workouts were often overlooked as she went from city to city, a casualty of long hours and a busy schedule. And, even though she did have a membership to a national gym with privileges at any of its locations, she hated the feeling of always being sold something and disliked that both the trainers and managers she worked with took very little interest in her personal needs and fitness goals.

She wanted something that allowed her to exercise with someone on her own schedule, and with people who valued customer service. That's how the idea for Kanthaka was born. Read the full story here.


Erik Halvorsen has reportedly left his position at the TMC Innovation Institute. Courtesy TMC

TMC Innovation Institute leader leaves the organization

TMC exited

Erik Halvorsen, director of the Texas Medical Center's Innovation Institute, has left his position, according to multiple reports.

TMC's medical device innovation team lead, Lance Black, was named as the interim replacement for Halvorsen, according to Xconomy. Black has been with TMC for almost two years.

Neither Halvorsen nor Black could not be reached for comment. This article will be updated as more information becomes available.

Halvorsen has lead the organization since 2015. Before that, he worked in various health technology focused roles in Boston. He oversaw TMC's accelerator program, TMCx. The program graduates around 20 companies per cohort, and there's two cohorts each year — one focused on medical devices, which just concluded with the Nov. 15 Demo Day, and the other, which is about to launch, focused on digital health. TMCx was recently given silver recognition from the Seed Accelerator Rankings Project.

In an interview with InnovationMap earlier this month, Halvorsen talked about his career and Houston's medical innovation ecosystem.

"One of the things that I knew moving to Houston from Boston was that the investment environment for life sciences wasn't as robust as Boston," he said in that interview. "I knew coming in that was going to be a bit of an issue. I also felt like we had the raw materials, that if we ran our program the right way and attracted those companies we needed, the dollars would flow. And that's really been the case."

These three entrepreneurs didn't see their careers coming. Courtesy photos

3 Houston innovators to know this week

Who's Who

The career paths of startup or innovation leaders isn't usually a direct path. All three of this week's innovators to know took a roundabout way to their current gigs, which included a leap of faith or two for each of them. If their winding careers are any indication, they've got more exciting leadership ahead.

Youngro Lee, CEO and co-founder of NextSeed

Courtesy of NextSeed

Starting off on Wall Street as a private equity lawyer, Youngro Lee knows money. And he knew when the Jobs Act went into effect several years ago, there was a huge opportunity for companies to raise money from non-accredited individual investors, rather than just the super wealthy private investors. He left his legal career to leverage this new law to start NextSeed, which is a platform for businesses to raise capital for from anybody. Read more here.

Jane Henry, founder and CEO of SeeHerWork

Courtesy of SeeHerWork

Jane Henry watched as her glove flew right off her hand when she was cleaning up after Hurricane Harvey — her house got three feet of mud, and she got the idea for her company. SeeHerWork goes above and beyond the normal "pink it and shrink it" approach to women's workwear. Henry wants to see female workers with better fitting safety gear. Read more here.

Erik Halvorsen, director of the TMC Innovation Institute

Courtesy of TMC

As a kid, Erik Halvorsen wanted to be a doctor — he even took the MCAT and was on track for med school. He decided to look into other avenues that combined his passion for medicine and his entrepreneurial spirit. As director of TMCx, he helps innovative medical technologies become standard practice in hospitals. Read more here.

Editor's note: Halvorsen reportedly left his position at TMC on December 13, 2018.

Erik Halvorsen is sparking a medical innovation revolution with TMCx. Courtesy of TMC

TMCx leader is ready for Houston's health care innovation ecosystem to fully bloom

MedTalk

Editor's note: Halvorsen reportedly left his position at TMC on December 13, 2018. The original article as it first published is below.

Erik Halvorsen describes himself as an impatient guy, which is why, rather than wait for Houston's medical startup culture to evolve to meet Boston's or Silicon Valley's, he's taking steps to change it now.

"The reality is Houston is not Boston or Silicon Valley, and it comes down to a couple things: access to capital and the pool of entrepreneurs running around," says Halvorsen, director of the TMC Innovation Institute.

But the Texas Medical Center is looking to change that in the health care sector with TMCx, its accelerator.

TMCx was recently given silver recognition from the Seed Accelerator Rankings Project. While it's an impressive feat, Halvorsen envisions TMCx rise through the ranks of that award over the next few years.

"For us, we're kind of competing with ourselves to be as good as we possibly can be."

TMCx graduates around 20 companies per cohort, and there's two cohorts each year — one focused on medical devices, which just concluded with the Nov. 15 Demo Day, and the other, which is about to launch, focused on digital health.

InnovationMap: How did you get your start in your industry?

Erik Halvorsen: From as young as I can remember, I wanted to be a medical doctor. Fast forward, all through undergraduate, I was pre-med. Took the MCAT, scored in the 99 percentile, but when it came time to apply to medical school, I chose not to. I ended up applying to a "tweener program" at the Medical College of Virginia in Richmond, and they had these master's programs where you would take all the first year's classes of medical school and do research in a particular discipline. I was doing research in biochemistry. I go through that whole program, and then I still wasn't sure I wanted to be a doctor or go to medical school, but I liked research. I got offered a full scholarship to do a Ph.D. program at the University of Virginia, but I didn't love being in the lab. I found an ad somewhere about an internship at the UVA Patent Foundation. It was basically taking early stage innovation, discoveries, and IP out of universities and medical centers and turning them into products, and what that's look like — whether it was startup companies or corporate partners, and that's when the lightbulb went off for me. I was really good at speaking the science to the business side, and then speaking the business and finance side to the scientists and doctors. The rest of my career became some version of playing in that in between space in helping translate ideas to ultimately get to the big companies and ultimately in the market to help patients.

IM: In your role at TMCx, you oversee the accelerator and what companies make it in. What does TMCx look for in its cohort?

EH: What we're looking for is what we think is cutting edge, and truly innovative addressing an unmet need. We consult with a lot of the hospitals here. I ask them what's keeping them up at night. That list helps me select the companies. If I see companies that are making cool products that meet one of these unmet needs in TMC, then I know that company will get traction if they were in town, and that's important.

IM: What's the process of picking the companies?

EH: We'll get 200 to 300 applications and interview about 75 companies for the 20 to 25 spots. When we interview, we get at what is their understanding of the current practice, competitive landscape, etc. It's also a good chance for us to glean a little bit of the personality of the teams we're bringing in. We learned a long time ago that we don't want to work with assholes. We go a long way to find the people who are in it for the right reasons. You have to be really smart and confident — you've got to be pretty self confident if you're think you're bringing a solution to a problem that no one has success doing before. But it has to be self confidence without arrogance.

IM: What's the economic impact of the accelerator?

EH: I think we're clearly a major piece of the Houston ecosystem. JLabs has 50 companies under their roof, and when you add TMCx and the coworking space, we have about 100 health care companies under our roof. When you think about the companies that came through our program, that's a total of 250 companies. Those companies are important to the ecosystem because they are out there telling the world about Texas, the medical center, and Houston. Their word of mouth is the reason we see the volume and the quality of the applications going up each year. A lot of our companies choose to stay in Houston.

IM: What sets TMCx apart from its competition?

EH: We don't take equity. That sets us apart. I think this is a major reason we've been able to attract companies that are more advanced — still startups, just far down the path. Those of the kinds of companies who would never consider an accelerator program that asks them to give up equity.

IM: Where does Houston's innovation sector have room for improvement?

EH: One of the things that I knew moving to Houston from Boston was that the investment environment for life sciences wasn't as robust as Boston. I knew coming in that was going to be a bit of an issue. I also felt like we had the raw materials, that if we ran our program the right way and attracted those companies we needed, the dollars would flow. And that's really been the case.

Another area we have to grow is international collaborations. We already have a high percentage of international applicants, but now we're trying to build these biobridges to other ecosystems where we can collaborate on two areas: research and innovation commercialization.

IM: What all are you excited about seeing from TMC3?

EH: I think it's really unique to Houston to bring all of these elements together in what I think is a well-designed manner. It will really transform the city. You're going to have big industry down there — a lot of those conversations are still ongoing. I mean, 116,000 medical employees and 10 million patients a year, these big health care companies want to be close to that.

This will be another way we can accelerate what we learn in the lab to treatment for patients. I'm really excited about it, and I think the startup companies we continue to bring to Houston and nurture in the TMC Innovation Institute will be a major part of bridging that gap between research and discovery to the big companies that will bring that product to market.

IM: What advice do you have for health-related startup companies?

EH: There are plenty of studies that have been done that have shown that the main reason companies fail is that there's no market for their product — and that's industry agnostic, but it's definitely true in health care. What we spend a lot of time in our program is helping the companies evaluate that and understand what their product market is — and really validating that people are going to use it and, more importantly, people are going to pay for it.

My advice would be not to just assume there's a need. Go figure out how to validate that it's a better technology and that people will use it and buy it.

------

Portions of this interview have been edited.

TMCx was nationally recognized by Seed Accelerator Rankings Project. Courtesy of TMCx

TMCx receives national award for unique startup accelerator program

x marks the spot

The Texas Medical Center has once again received national acclaim — this time, for its innovation.

Seed Accelerator Rankings Project selected TMCx for a "Silver" distinction in its 2018 awards. SARP evaluated accelerators' success and selected 25 honorees in four categories — Platinum Plus, Platinum, Gold, and Silver. The distinction is aimed to help startups navigate accelerators and find the ones of quality.

SARP objectively measures the impact of these accelerator programs, says Erik Halvorsen, director of the TMC Innovation Institute. There simply isn't non-biased information about accelerators out there. Most startups are forced to rely on marketing materials from the programs.

"One of the things I say often is, 'If you see one accelerator, you've seen one accelerator,' meaning they are all different," Halvorsen says. "There are so many out there, and it can be confusing for startups who think they are all the same."

Now in its fifth year, SARP collected sensitive information, such as fundraising and valuations, and evaluated each accelerator to select the top 25.

The TMCx accelerator program has two cohorts a year, alternating between digital health and medical device focuses. Currently, TMCx has 23 medical device companies participating in the accelerator. Halvorsen says what sets TMCx apart is its focus on medicine, but also the fact that the accelerator doesn't take equity of its companies. Other programs require anywhere from 3 to 7 percent equity in the company in exchange for participation.

"I think this is a major reason we've been able to attract companies that are more advanced — still startups, just further down the path. Those are the kinds of companies who would never consider an accelerator program that asks them to give up equity."

This is the first year TMCx has made it on to the SARP listing, but Halvorsen says it won't be the last.

"I love the fact that there's still a couple levels above where we're ranked, so we definitely have something to shoot for as we grow and improve our program," he says. "For us, we're kind of competing with ourselves to be as good as we possibly can be."

TMCx's fall cohort participants showcase their work in a final presentation called Demo Day, which is on November 14.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston-area lab grows with focus on mobile diagnostics and predictive medicine

mobile medicine

When it comes to healthcare, access can be a matter of life and death. And for patients in skilled nursing facilities, assisted living or even their own homes, the ability to get timely diagnostic testing is not just a convenience, it’s a necessity.

That’s the problem Principle Health Systems (PHS) set out to solve.

Founded in 2016 in Clear Lake, Texas, PHS began as a conventional laboratory but quickly pivoted to mobile diagnostics, offering everything from core blood work and genetic testing to advanced imaging like ultrasounds, echocardiograms, and X-rays.

“We were approached by a group in a local skilled nursing facility to provide services, and we determined pretty quickly there was a massive need in this area,” says James Dieter, founder, chairman and CEO of PHS. “Turnaround time is imperative. These facilities have an incredibly sick population, and of course, they lack mobility to get the care that they need.”

What makes PHS unique is not only what they do, but where they do it. While they operate one of the largest labs serving skilled nursing facilities in the state, their mobile teams go wherever patients are, whether that’s a nursing home, a private residence or even a correctional facility.

Diagnostics, Dieter says, are at the heart of medical decision-making.

“Seventy to 80 percent of all medical decisions are made from diagnostic results in lab and imaging,” he says. “The diagnostic drives the doctor’s or the provider’s next move. When we recognized a massive slowdown in lab results, we had to innovate to do it faster.”

Innovation at PHS isn’t just about speed; it’s about accessibility and precision.

Chris Light, COO, explains: “For stat testing, we use bedside point-of-care instruments. Our phlebotomists take those into the facilities, test at the bedside, and get results within minutes, rather than waiting days for results to come back from a core lab.”

Scaling a mobile operation across multiple states isn’t simple, but PHS has expanded into nine states, including Texas, Oklahoma, Kansas, Missouri and Arizona. Their model relies on licensed mobile phlebotomists, X-ray technologists and sonographers, all trained to provide high-level care outside traditional hospital settings.

The financial impact for patients is significant. Instead of ambulance rides and ER visits costing thousands, PHS services often cost just a fraction, sometimes only tens or hundreds of dollars.

“Traditionally, without mobile diagnostics, the patient would be loaded into a transportation vehicle, typically an ambulance, and taken to a hospital,” Dieter says. “Our approach is a fraction of the cost but brings care directly to the patients.”

The company has also embraced predictive and personalized medicine, offering genetic tests that guide medication decisions and laboratory tests that predict cognitive decline from conditions like Alzheimer's and Parkinson’s.

“We actively look for complementary services to improve patient outcomes,” Dieter says. “Precision medicine and predictive testing have been a great value-add for our providers.”

Looking to the future, PHS sees mobile healthcare as part of a larger trend toward home-based care.

“There’s an aging population that still lives at home with caretakers,” Dieter explains. “We go into the home every day, whether it’s an apartment, a standalone home, or assisted living. The goal is to meet patients where they are and reduce the need for hospitalization.”

Light highlighted another layer of innovation: predictive guidance.

“We host a lot of data, and labs and imaging drive most treatment decisions,” Light says. “We’re exploring how to deploy diagnostics immediately based on results, eliminating hours of delay and keeping patients healthier longer.”

Ultimately, innovation at PHS isn’t just about technology; it’s about equity.

“There’s an 11-year life expectancy gap between major metro areas and rural Texas,” Dieter says. “Our innovation has been leveling the field, so everyone has access to high-quality diagnostics and care, regardless of where they live.”

Aegis Aerospace appoints Houston space leader as new president

moving up

Houston-based Aegis Aerospace's current chief strategy officer, Matt Ondler, will take on the additional role of president on Jan. 1. Ondler will succeed Bill Hollister, who is retiring.

“Matt's vision, experience, and understanding of our evolving markets position us to build on our foundation and pursue new frontiers,” Stephanie Murphy, CEO of Aegis Aerospace, said in a news release.

Hollister guided Aegis Aerospace through expansion and innovation in his three years as president, and will continue to serve in the role of chief technology officer (CTO) for six months and focus on the company's technical and intellectual property frameworks.

"Bill has played an instrumental role in shaping the success and growth of our company, and his contributions leave an indelible mark on both our culture and our achievements," Murphy said in a news release.

Ondler has a background in space hardware development and strategic leadership in government and commercial sectors. Ondler founded subsea robots and software company Houston Mechatronics, Inc., now known as Nauticus Robotics, and also served as president, CTO and CSO during a five-year tenure at Axiom Space. He held various roles in his 25 years at NASA and was also named to the Texas Aerospace Research and Space Economy Consortium Executive Committee last year.

"I am confident that with Matt at the helm as president and Bill supporting us as CTO, we will continue to build on our strong foundation and further elevate our impact in the space industry," Murphy said in a news release. "Matt's vision, experience, and understanding of our evolving markets position us to build on our foundation and pursue new frontiers."

Rice University launches new center to study roots of Alzheimer’s and Parkinson’s

neuro research

Rice University launched its new Amyloid Mechanism and Disease Center last month, which aims to uncover the molecular origins of Alzheimer’s, Parkinson’s and other amyloid-related diseases.

The center will bring together Rice faculty in chemistry, biophysics, cell biology and biochemistry to study how protein aggregates called amyloids form, spread and harm brain cells. It will serve as the neuroscience branch of the Rice Brain Institute, which was also recently established.

The team will work to ultimately increase its understanding of amyloid processes and will collaborate with the Texas Medical Center to turn lab discoveries into real progress for patients. It will hold its launch event on Jan. 21, 2026, and hopes to eventually be a launchpad for future external research funding.

The new hub will be led by Pernilla Wittung-Stafshed, a Rice biophysicist and the Charles W. Duncan Jr.-Welch Chair in Chemistry.

“To make a real difference, we have to go all the way and find a cure,” Wittung-Stafshede said in a news release. “At Rice, with the Amyloid Mechanism and Disease Center as a catalyst, we have the people and ideas to open new doors toward solutions.”

Wittung-Stafshede, who was recruited to Rice through a Cancer Prevention and Research Institute of Texas grant this summer, has led pioneering work on how metal-binding proteins impact neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases. Her most recent study, published in Advanced Science, suggests a new way of understanding how amyloids may harm cells and consume the brain’s energy molecule, ATP.

According to Alzheimer’s Disease International, neurodegenerative disease cases could reach around 78 million by 2030 and 139 million by 2050. Wittung-Stafshede’s father died of dementia several years ago.

“This is close to my heart,” Wittung-Stafshede added in the news release. “Neurodegenerative diseases such as dementia, Alzheimer’s and Parkinson’s are on the rise as people live longer, and age is the largest risk factor. It affects everyone.”
View All Listings